Association of circulating vaspin levels and patients with metabolic-associated fatty liver disease: a systematic review and meta-analysis

Mantovani A, Dalbeni A. Recent Developments in NAFLD. Int J Mol Sci. 2022;23:2882.

PubMed  PubMed Central  Article  Google Scholar 

Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology. 2020;72:1605–16.

PubMed  Article  Google Scholar 

Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47–64.

PubMed  Article  Google Scholar 

Eslam M, George J. MAFLD: now is the time to capitalize on the momentum. J Hepatol. 2021;74:1262–3.

PubMed  Article  Google Scholar 

Petäjä EM, Yki-Järvinen H. Definitions of Normal liver fat and the Association of Insulin Sensitivity with acquired and genetic NAFLD-A systematic review. Int J Mol Sci. 2016;17:633.

PubMed Central  Article  CAS  Google Scholar 

Carr RM, Oranu A, Khungar V. Nonalcoholic fatty liver disease. Gastroenterol Clin N Am. 2016;45:639–52.

Article  Google Scholar 

Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908–22.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Leite NC, Villela-Nogueira CA, Cardoso CR, Salles GF. Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment. World J Gastroenterol. 2014;20:8377–92.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7:313–24.

PubMed  Article  Google Scholar 

Muzurović E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. METABOLISM. 2021;119:154770.

PubMed  Article  CAS  Google Scholar 

Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism. 2016;65:1062–79.

CAS  PubMed  Article  Google Scholar 

Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med. 2009;9:299–314.

CAS  PubMed  Article  Google Scholar 

Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia. 2016;59:30–43.

CAS  PubMed  Article  Google Scholar 

Hu J, Ke Y, Wu F, Liu S, Ji C, Zhu X, et al. Circulating Irisin levels in patients with nonalcoholic fatty liver disease: a systematic review and Meta-analysis. Gastroenterol Res Pract. 2020;2020:8818191.

PubMed  PubMed Central  Article  Google Scholar 

Kurowska P, Mlyczyńska E, Dawid M, Jurek M, Klimczyk D, Dupont J, et al. Review: Vaspin (SERPINA12) expression and function in endocrine cells. Cells. 2021;10:1710.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Escoté X, Gómez-Zorita S, López-Yoldi M, Milton-Laskibar I, Fernández-Quintela A, Martínez JA, et al. Role of Omentin, Vaspin, Cardiotrophin-1, TWEAK and NOV/CCN3 in obesity and diabetes development. Int J Mol Sci. 2017;18:1770.

PubMed Central  Article  CAS  Google Scholar 

Rashad NM, Ahmed HS, Ashour W, Yousef MS. Association of vaspin gene expression and its serum level on the risk of ischemic stroke in type 2 diabetic Egyptian patients: prospective case-control study. Biotechnol Appl Biochem. 2020;67:912–9.

CAS  PubMed  Article  Google Scholar 

Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160.

PubMed  PubMed Central  Article  Google Scholar 

Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.

PubMed  Article  Google Scholar 

Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.

CAS  PubMed  Article  Google Scholar 

Schmidt FL, Oh IS, Hayes TL. Fixed- versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results. Br J Math Stat Psychol. 2009;62:97–128.

PubMed  Article  Google Scholar 

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

PubMed  PubMed Central  Article  Google Scholar 

Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ismail SM, Elgendy NA, Sayed ZH, Hameed AA, Ahmad IH, Althoqapy AA. Chemerin and vaspin as noninvasive biomarkers in the pathogenesis and diagnosis of non-alcoholic fatty liver disease. Am J Med Med Sci. 2019;9:7–13.

Google Scholar 

Aktas B, Yilmaz Y, Eren F, Yonal O, Kurt R, Alahdab YO, et al. Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. Metabolism. 2011;60:544–9.

CAS  PubMed  Article  Google Scholar 

Fu SJ, Yang ZX. Correlation between serum HMGB-1, IL-1β, Vaspin levels and HOMA-IR in patients with nonalcoholic fatty liver disease. Int J Lab Med. 2019;40(2132–2134):2138.

Google Scholar 

Genc H, Dogru T, Tapan S, Kara M, Ercin CN, Aslan F, et al. Circulating vaspin and its relationship with insulin sensitivity, adiponectin, and liver histology in subjects with non-alcoholic steatohepatitis. Scand J Gastroenterol. 2011;46:1355–61.

CAS  PubMed  Article  Google Scholar 

Kukla M, Zwirska-Korczala K, Hartleb M, Waluga M, Chwist A, Kajor M, et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2010;45:235–42.

CAS  PubMed  Article  Google Scholar 

Montazerifar F, Bakhshipour AR, Karajibani M, Torki Z, Dashipour AR. Serum omentin-1, vaspin, and apelin levels and central obesity in patients with nonalcoholic fatty liver disease. J Res Med Sci. 2017;22:70.

PubMed  PubMed Central  Article  Google Scholar 

Polyzos SA, Kountouras J, Polymerou V, Papadimitriou KG, Zavos C, Katsinelos P. Vaspin, resistin, retinol-binding protein-4, interleukin-1α and interleukin-6 in patients with nonalcoholic fatty liver disease. Ann Hepatol. 2016;15:705–14.

CAS  PubMed  Google Scholar 

Su XL, Wang TS, Zhang YJ. Expression and significance of serum Omentin-1 and vaspin in patients with nonalcoholic fatty liver disease. Liver. 2021;26:67–70.

Google Scholar 

Waluga M, Kukla M, Kotulski R, Zorniak M, Boryczka G, Kajor M, et al. Omentin, vaspin and irisin in chronic liver diseases. J Physiol Pharmacol. 2019;70:277.

CAS  Google Scholar 

Xia W, Wen SL, Zhang L, Jia HY. Changes in Vaspin levels in elderly patients with type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease. Chinese J Diabetes. 2011;19:691–4.

CAS  Google Scholar 

Yan LL, Lu J, Jia HY. Serum Chemerin, Vaspin and TXNIP levels in patients with non-alcoholic fatty liver disease and their correlation analysis. Guizhou Med J. 2019;43:364–6.

CAS  Google Scholar 

Yilmaz Y, Kurt R, Gurdal A, Alahdab YO, Yonal O, Senates E, et al. Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. Atherosclerosis. 2011;217:125–9.

CAS  PubMed  Article  Google Scholar 

Yu HY, Di FS, Wang L, Li Q, Jia GY, Zhang J, et al. Correlation between plasma Vaspin and metabolic parameters in diabetic patients with fatty liver. Tianjin Med J. 2012;40:1121–4.

CAS  Google Scholar 

Younossi ZM. Non-alcoholic fatty liver disease - a global public health perspective. J Hepatol. 2019;70:531–44.

PubMed  Article  Google Scholar 

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–57.

PubMed  Article  Google Scholar 

Schattenberg JM, Schuppan D. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr Opin Lipidol. 2011;22:479–88.

CAS  PubMed  Article  Google Scholar 

Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol. 2013;28(Suppl 1):68–76.

CAS  PubMed  Article  Google Scholar 

Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A. 2005;102:10610–5.

CAS  PubMed  PubMed Central  Article  Google Scholar 

留言 (0)

沒有登入
gif